Ads
related to: plx
Search results
PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose...
Simply Wall St. via Yahoo Finance· 2 years agoInsiders who acquired US$65k worth of PLx Pharma Inc.'s (NASDAQ:PLXP) stock at an average price of...
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoPLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively,...
PLx Pharma (NASDAQ:PLXP) shareholders have endured a 89% loss from investing in the stock a year ago
Simply Wall St. via Yahoo Finance· 2 years agoThe art and science of stock market investing requires a tolerance for losing money on some of the...
PLx Pharma Looks At Alternatives As Vazalore Faces Macro Headwinds
Benzinga via Yahoo Finance· 2 years agoJMP Securities has downgraded PLx Pharma Inc (NASDAQ: PLXP) to Market Perform from Market Outperform...
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Benzinga via Yahoo Finance· 2 years agoPluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of...
Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results
GuruFocus.com via Yahoo Finance· 7 months agoProtalix BioTherapeutics Inc (PLX) reported a net income of $14.36 million for Q3 2023, a...
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Benzinga via Yahoo Finance· 2 years agoYesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix...
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Zacks via Yahoo Finance· 2 years agoPluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating...
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus...
Benzinga via Yahoo Finance· 1 year agoThe FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio...
